Pacira reports Oct 2022 preliminary net sales of $54.9M; EXPAREL average daily sales 106% of prior year

Pacira BioSciences, Inc.

Preliminary unaudited net product sales of $54.9M for October 2022.
EXPAREL net sales $45.0M (vs $42.5M Oct 2021); average daily sales 106% of prior year.
ZILRETTA net sales $8.6M (acquired Nov 2021); iovera° net sales $1.3M (vs $1.2M).
Company not providing FY2022 revenue/gross margin guidance due to COVID-19 uncertainty.
CEO Dave Stack reiterates confidence in double-digit growth and value creation from partnerships.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pacira BioSciences, Inc. reported month ended October 31, 2022 results: revenue $54.9 million.

Period: month ended October 31, 2022
Revenue: $54.9 million
Result: preliminary results

Exact text from the filing

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022

View on SEC.gov

Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-22-000070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.